Eli Lilly and Company (LLY) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for LLY is $1,283.64 — 8.9% above the latest price of $1178.79.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The primary driver for Eli Lilly's bullish case is the continued robust performance and market expansion of its GLP-1 franchise, especially Mounjaro and Zepbound, which are significant revenue generators for diabetes and weight loss.. The recent approval and launch of Foundayo, an oral GLP-1, and positive Phase 3 results for retatrutide (a triple incretin agonist), represent strong pipeline momentum and potential future blockbusters.. Strategic acquisitions, such as the recent deal for AtaiBeckley, are actively diversifying the company's pipeline into high-growth areas like neuroscience, further strengthening its long-term growth prospects.. The company's management has consistently raised financial guidance, reflecting strong underlying business performance and confidence in future growth.
Bear Case
Eli Lilly faces significant challenges, including a notably high valuation with a P/E ratio above 40x, which raises concerns about potential overvaluation.. The increasing competitive intensity in the GLP-1 market, with rivals like Novo Nordisk and other major pharmaceutical companies developing their own obesity and diabetes treatments, could exert pressure on market share and pricing.. Furthermore, pricing and reimbursement scrutiny from payers and potential regulatory changes, such as IRA drug pricing negotiations, pose risks to the profitability of its key GLP-1 products.. Pipeline execution risk remains a factor, as late-stage failures for any of its numerous programs, particularly high-profile assets like retatrutide, could negatively impact future revenue forecasts.. The company's hypergrowth is heavily concentrated in its GLP-1 franchise, making it sensitive to any pricing, supply, or safety shocks within this area.
Model-assessed risk level: Medium
Key Catalysts to Watch
Continued robust uptake and broader market penetration of Foundayo (oral GLP-1 for weight loss and diabetes).
Successful clinical trial outcomes and regulatory approvals for key pipeline assets, especially retatrutide, for expanded indications.
Synergistic benefits and successful integration of recent strategic acquisitions, particularly in the neuroscience pipeline.
Strong performance in upcoming quarterly earnings reports and potential upward revisions to full-year financial guidance.
Further advancements and potential regulatory milestones for its Alzheimer's disease drug pipeline.
Technical Backdrop
RSI-14
61.9
50-Day MA
$1042.51
200-Day MA
$925.25
From 52-Wk High
-4.6%
Full momentum breakdown: Is LLY overbought or oversold?
Model Notes
Eli Lilly and Company is a global pharmaceutical powerhouse, renowned for its innovative therapies across cardiometabolic health, oncology, immunology, and neuroscience. The company has demonstrated robust financial performance, largely driven by its highly successful GLP-1 franchise, including Mounjaro and Zepbound. It maintains a strong and actively advancing drug pipeline and has recently undertaken strategic acquisitions to diversify its therapeutic areas. Despite a high market valuation, analysts generally hold a positive outlook for the company, anticipating sustained growth from its innovative product portfolio and extensive research and development efforts.
Eli Lilly's stock exhibits a generally positive technical outlook, trending within a rising channel in the medium term. Most moving averages, including the 20-day, 50-day, 100-day, and 200-day exponential and simple moving averages, indicate 'Buy' signals.. The Moving Averages Convergence Divergence (MACD) also suggests a 'Buy'.. The Relative Strength Index (RSI) is in a neutral to buy range.. The price is currently above key support levels.. However, some short-term moving averages (like the 8-day and 20-day simple and exponential moving averages) have shown 'Sell' signals, indicating potential for minor pullbacks.
Current Street Context
July 16, 2026The AI price target for Eli Lilly and Company is $1,335.70. Analyst sentiment for LLY is generally positive, driven by its diverse portfolio and strategic investments in new products. Analysts anticipate significant earnings growth for the company in the coming year. Eli Lilly is expected to announce its Q2 2026 earnings on August 5, 2026. Analysts are projecting an EPS of $8.84 for this upcoming report. The company's robust pipeline of medications awaiting FDA approval, particularly in areas such as oncology, immunology, and neurodegeneration, are considered key drivers for its future growth prospects. Price targets are estimates and not guaranteed outcomes.
Frequently Asked Questions
What is the price target for LLY?
How is this forecast generated?
How accurate are stock price predictions?
Will LLY stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews LLY’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Overbought or Oversold?
Updated daily
LLY: Why Is It Moving?
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers